Avenue

Republic Bank Continues Growth in Greater Cincinnati Area with Opening of New Banking Center in Bellevue in Campbell County

Retrieved on: 
Monday, March 27, 2023

Republic Bank & Trust Company (“Republic” or the “Bank”) announces the opening of a new banking center in Bellevue, Kentucky at 119 Fairfield Avenue, expanding its service area into Campbell County and the Greater Cincinnati area.

Key Points: 
  • Republic Bank & Trust Company (“Republic” or the “Bank”) announces the opening of a new banking center in Bellevue, Kentucky at 119 Fairfield Avenue, expanding its service area into Campbell County and the Greater Cincinnati area.
  • View the full release here: https://www.businesswire.com/news/home/20230327005508/en/
    The banking center opened on Tuesday, March 14, 2023, and has already begun servicing existing and new Republic clients in the area.
  • “We’re thrilled to join the growing and dynamic Bellevue community and expand our presence with our fourth banking center in Northern Kentucky,” said Jason Payne, Northern Kentucky Managing Director at Republic Bank, and longtime resident of the Greater Cincinnati area.
  • Republic’s new Bellevue location joins its Covington and Newport locations in the fast-growing area, located minutes from downtown Cincinnati.

FOX CORPORATION UNVEILS "FOX FUTURE" STUDIO LOT PROJECT

Retrieved on: 
Thursday, March 16, 2023

NEW YORK and LOS ANGELES, March 16, 2023 /PRNewswire/ -- Nearly 100 years since filming began on the FOX Studio Lot, Fox Corporation (Nasdaq: FOXA, FOX; "FOX" or the "Company") has announced the creation of the FOX FUTURE Studio Lot Project, which seeks to build the studio of the future amid the continued evolution of Century City.

Key Points: 
  • Generating an Expected $1.5 Billion in Direct Local Economic Impact, the FOX FUTURE Studio Lot Project Proposes Nine New Sound Stages, Modern Production Facilities and Premium Commercial Office Space while Honoring the Legacy of the Iconic Property
    NEW YORK and LOS ANGELES, March 16, 2023 /PRNewswire/ -- Nearly 100 years since filming began on the FOX Studio Lot, Fox Corporation (Nasdaq: FOXA, FOX; "FOX" or the "Company") has announced the creation of the FOX FUTURE Studio Lot Project, which seeks to build the studio of the future amid the continued evolution of Century City.
  • "The FOX Studio Lot is one of the most iconic and treasured production locations in the history of entertainment and is a rich part of our history," said Lachlan Murdoch, Executive Chair and CEO, Fox Corporation.
  • Additionally, the project will create a LEED-Platinum designed media campus office building to support FOX Studio Lot operations.
  • As part of Fox Corporation, the FOX Studio Lot has a strong commitment to sustainability.

Montclair Hospitality Group Partners with Famed Iron Chef Masaharu Morimoto to Launch New Dining Concepts

Retrieved on: 
Wednesday, March 15, 2023

MONTCLAIR, N.J., March 15, 2023 /PRNewswire/ -- Montclair Hospitality Group (MHG) the chef-driven, global hospitality company focused on curating the world's leading dining concepts, today announces an exclusive partnership with famed Iron Chef Masaharu Morimoto. Known around the world as the star of Iron Chef and Iron Chef America, Chef Morimoto has garnered popular acclaim for his seamless integration of Western and Japanese ingredients. He has effectively created a signature style and positioned himself as one of today's foremost chefs. MHG and Morimoto's new restaurant partnership will include a new restaurant to anchor Fortress Developments new InterContinental Hotel – Bellevue at the Avenue, bringing a new Morimoto concept to Northwest America with plans for a luxury sushi dining concept.

Key Points: 
  • MONTCLAIR, N.J., March 15, 2023 /PRNewswire/ -- Montclair Hospitality Group (MHG) the chef-driven, global hospitality company focused on curating the world's leading dining concepts, today announces an exclusive partnership with famed Iron Chef Masaharu Morimoto.
  • Known around the world as the star of Iron Chef and Iron Chef America, Chef Morimoto has garnered popular acclaim for his seamless integration of Western and Japanese ingredients.
  • The partnership between MHG and Chef Morimoto comes on the heels of exciting 2023 milestones for the leading hospitality group.
  • The partnership with Iron Chef Morimoto comes in addition to upcoming MHG concepts and planned launches across the country.

Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate Updates

Retrieved on: 
Wednesday, March 8, 2023

The Company expects to provide an update on the outcome of the meeting in April 2023, after receipt of the meeting minutes from the FDA.

Key Points: 
  • The Company expects to provide an update on the outcome of the meeting in April 2023, after receipt of the meeting minutes from the FDA.
  • As disclosed in September 2022, Avenue received meeting minutes from the FDA regarding a Type A meeting conducted on August 9, 2022, for IV Tramadol.
  • On March 7, 2023, Alexandra MacLean, M.D., the Chief Executive Officer of Avenue, was appointed to the Board of Directors.
  • In addition, Jay Kranzler, M.D., Ph.D., a current Director of Avenue, was appointed as the Chairman, true to Dr. Kranzler’s expertise in the neurosciences.

AnnJi Pharmaceutical Announced A Licensing Agreement With Avenue Therapeutics To Develop And Commercialize AJ201, A First-In-Class Clinical Asset For The Treatment Of Kennedy's Disease

Retrieved on: 
Friday, March 10, 2023

In addition, AnnJi will retain the manufacturing right to provide clinical and commercial supply of AJ201 to Avenue under agreed sale price and will be compensated for any Avenue's sublicense activity.

Key Points: 
  • In addition, AnnJi will retain the manufacturing right to provide clinical and commercial supply of AJ201 to Avenue under agreed sale price and will be compensated for any Avenue's sublicense activity.
  • This agreement is one of the largest license deals for a small molecule drug in early Phase 1b/2a clinical development in the past twenty-four months.
  • AJ201 is currently being investigated in a multicenter, randomized, double-blind clinical trial in six clinical sites across the U.S.
  • The study aims to evaluate the safety and clinical response of AJ201 in Kennedy's Disease patients.

Granite Construction Awarded Contract for Ave J Interchange Improvements in Lancaster, California

Retrieved on: 
Tuesday, March 7, 2023

Granite (NYSE:GVA) has been selected by the City of Lancaster to lead an approximately $30 million contract for various improvements to the Avenue J (Ave J) Interchange at California State Route 14 (SR 14).

Key Points: 
  • Granite (NYSE:GVA) has been selected by the City of Lancaster to lead an approximately $30 million contract for various improvements to the Avenue J (Ave J) Interchange at California State Route 14 (SR 14).
  • The project scope consists of widening the existing northside on- and off-ramps, constructing new on- and off-ramps on the south side of Ave J, and building four new retaining walls.
  • To complete the project, Granite will supply approximately 17,000 tons of asphalt materials from its Big Rock Facility in nearby Llano, CA.
  • “The City of Lancaster has been a great partner since we started operating in the Antelope Valley 35 years ago,” said Granite Area Manager Andrew Burk.

Clearwater Analytics Announces Pricing of Secondary Offering of Class A Common Stock

Retrieved on: 
Thursday, March 9, 2023

BOISE, Idaho, March 8, 2023 /PRNewswire/ -- Clearwater Analytics Holdings, Inc. ("Clearwater Analytics" or the "Company") (NYSE: CWAN), a leading provider of SaaS-based investment accounting, reporting, and analytics solutions, today announced the pricing of its underwritten secondary public offering of its Class A common stock priced at a price to the public of $15.00 per share.

Key Points: 
  • BOISE, Idaho, March 8, 2023 /PRNewswire/ -- Clearwater Analytics Holdings, Inc. ("Clearwater Analytics" or the "Company") (NYSE: CWAN), a leading provider of SaaS-based investment accounting, reporting, and analytics solutions, today announced the pricing of its underwritten secondary public offering of its Class A common stock priced at a price to the public of $15.00 per share.
  • The offering consists of 13,000,000 shares of Class A common stock to be sold by certain affiliates of Welsh, Carson, Anderson & Stowe (collectively, the "Selling Stockholders").
  • The Company will not receive any proceeds from the sale of the Company's Class A common stock by the Selling Stockholders.
  • The Company's Class A common stock is listed on the New York Stock Exchange under the ticker symbol "CWAN."

Clearwater Analytics Announces Launch of Secondary Offering of Class A Common Stock

Retrieved on: 
Wednesday, March 8, 2023

BOISE, Idaho, March 8, 2023 /PRNewswire/ -- Clearwater Analytics Holdings, Inc. ("Clearwater Analytics" or the "Company") (NYSE: CWAN), a leading provider of SaaS-based investment accounting, reporting, and analytics solutions, today announced that it has launched an underwritten secondary public offering of an aggregate of 13,000,000 shares of the Company's Class A common stock.

Key Points: 
  • BOISE, Idaho, March 8, 2023 /PRNewswire/ -- Clearwater Analytics Holdings, Inc. ("Clearwater Analytics" or the "Company") (NYSE: CWAN), a leading provider of SaaS-based investment accounting, reporting, and analytics solutions, today announced that it has launched an underwritten secondary public offering of an aggregate of 13,000,000 shares of the Company's Class A common stock.
  • The Company is conducting a resale of Class A common stock on behalf of certain affiliates of Welsh, Carson, Anderson & Stowe (collectively, the "Selling Stockholders").
  • The Company will not receive any proceeds from the sale of the Company's Class A common stock by the Selling Stockholders.
  • The Company's Class A common stock is listed on the New York Stock Exchange under the ticker symbol "CWAN."

Vistra to Create "Vistra Vision," a Leading Zero-Carbon Generation and Retail Platform, Through the Acquisition of Energy Harbor

Retrieved on: 
Monday, March 6, 2023

IRVING, Texas, March 6, 2023 /PRNewswire/ -- Today, Vistra Corp. (NYSE: VST) announced that it has executed a definitive agreement with Energy Harbor Corp., pursuant to which Energy Harbor will merge with and into a newly-formed subsidiary of Vistra. The transaction will combine Energy Harbor's nuclear and retail businesses with Vistra's nuclear and retail businesses and Vistra Zero renewables and storage projects under a newly-formed subsidiary holding company, referred to generally as "Vistra Vision." This combination creates a leading integrated retail electricity and zero-carbon generation company with the second-largest competitive nuclear fleet in the country, along with a growing renewables and energy storage portfolio. The agreement has been approved by both companies' boards of directors. Sufficient stockholder approval for the transaction has been committed through support agreements signed by a majority of the Energy Harbor stockholders.

Key Points: 
  • Consideration to Energy Harbor for this combination includes $3 billion cash and a 15% ownership interest in Vistra Vision; in addition, Vistra Vision will assume ~$430 million of net debt from Energy Harbor.
  • Vistra will own 85% of Vistra Vision as well as 100% of the entities holding its remaining conventional generation assets, referred to generally as "Vistra Tradition."
  • Sufficient stockholder approval for the transaction has been committed through support agreements signed by a majority of the Energy Harbor stockholders.
  • Burke concluded, "We look forward to welcoming the Energy Harbor generation and retail teams in Ohio and Pennsylvania to Vistra.

Avenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulbar Muscular Atrophy

Retrieved on: 
Thursday, March 2, 2023

“The license for AJ201 brings a cutting-edge asset into Avenue’s pipeline that is the lead molecule in the clinic to treat Kennedy’s Disease, a debilitating rare neuromuscular disorder.

Key Points: 
  • “The license for AJ201 brings a cutting-edge asset into Avenue’s pipeline that is the lead molecule in the clinic to treat Kennedy’s Disease, a debilitating rare neuromuscular disorder.
  • SBMA is a rare, inherited, X-linked genetic neuromuscular disease primarily affecting men.
  • The weakening of the bulbar muscles affects chewing, speech and swallowing, with patients prone to choking or inhaling foods or liquids, resulting in airway infection.
  • This study aims to evaluate the safety and clinical response of AJ201 in patients suffering from SBMA.